Do Antibiotic-Loaded Calcium Sulfate Beads Improve Outcomes After Debridement, Antibiotics, and Implant Retention? A Matched Cohort Study

T. David Tarity, MD, William Xiang, BS, Christopher W. Jones, MD PhD, Ioannis Gkiatas, MD, PhD, Allina Nocon, PhD, Nicolas A. Selemon, BA, Alberto Carli, MD, Peter K. Sculco, MD

Stavros Niarchos Foundation Complex Joint Reconstruction Center, Hospital for Special Surgery, New York, NY, USA
Adult Reconstruction and Joint Replacement, Hospital for Special Surgery, New York, NY, USA

Abstract

Background: Dissolvable antibiotic-loaded calcium sulfate beads are used as an intraoperative adjunct during debridement with antibiotics and implant retention (DAIR) for periprosthetic joint infections (PJI) to reduce the historically higher failure rates than one- or two-stage exchange. This study evaluated clinical outcomes after DAIRs performed with and without these antibiotic beads. The primary outcome was post-DAIR failure secondary to recurrent PJI at 2 years. The secondary outcome was early failure secondary to recurrent PJI within 90 days.

Material and methods: DAIRs performed for acute or acute hematogenous PJI at a single institution were retrospectively identified between 2013 and 2018. All DAIRs with adjunctive antibiotic beads (cases) were then exactly matched to a cohort of DAIRs without beads (controls) based on Charlson Comorbidity Index. The McNemar’s test and Wilcoxon signed-rank test were used to evaluate differences in outcomes and patient characteristics.

Results: Twenty DAIR cases (with antibiotic beads) were matched with 20 DAIR controls. There was no difference in age, sex, body mass index, joint, erythrocyte sedimentation rate, C-reactive protein, microbiology profile, antibiotic-resistance profile, or intraoperative lavage adjuncts between groups. There were no statistically significant differences between cases and controls for either overall infection-related failure at 2 years (P = .21) or early infection-related failure at 90 days (P = 1.00).

Conclusion: Adjunctive dissolvable antibiotic-loaded calcium sulfate beads did not reduce the incidence of recurrent PJIs at 2 years or 90 days postoperatively after DAIR. Given the added cost of these antibiotic dissolvable beads without clinical benefits, we cannot recommend their use as an adjunct treatment during DAIRs.

Introduction

In total hip (THA) and total knee arthroplasty (TKA), periprosthetic joint infection (PJI) significantly increases morbidity and carries a 5-year mortality rate higher than that of many cancers [1,2]. PJI after THA and TKA continues to be a leading cause of revision worldwide [3]. Current treatment options for PJI after THA and TKA include one-stage revision, two-stage revision, and debridement with antibiotics and implant retention (DAIR) [4]. Of these, DAIR represents the least invasive option for surgical PJI management, with previous studies reporting shorter hospital stays and lower cost in addition to functional outcomes that are comparable to primary total joint arthroplasty [5-7]. Unfortunately, the efficacy of DAIR for PJI treatment remains unclear, with reported failure rates of DAIR procedures in the literature varying from 0% to as much as 84% [8-11].

One of the reasons for increased failure compared with one-stage or two-stage exchange and the variable outcomes reported after DAIR is retained biofilm formation on orthopedic implants.
Unfortunately, pulsatile lavage with or without antibiotics is ineffective at eradicating bacterial and/or fungal biofilms [13], suggesting that minimally invasive or arthroscopy-based procedures are ineffective in achieving pathogen control. Therefore, current consensus recommendations describing DAIR call for a wide, excisional debridement of surrounding tissues and vigorous scrubbing of all implant surfaces. Unfortunately, this alone does not guarantee total biofilm removal.

Additional intraoperative measures have been introduced to improve DAIR outcomes, which include chemical lavage with adjunctive microbicidal solutions such as povidone-iodine, chlorhexidine, and peroxide, as well as topical antibiotic powder (usually vancomycin) to improve biofilm eradication. The combination of vancomycin powder and povidone-iodine lavage was demonstrated to reduce DAIR failure from 37% to 16.7% at approximately 2-year follow-up [14]. Intrarosseous antibiotics have also been proposed as an adjuvant technique to increase local tissue antibiotic concentration. A very recent study with minimum 1-year follow-up found that intrarosseous vancomycin was efficacious for DAIR survivorship when used to treat acute PJI, resulting in an eradication rate of 93.1%, but not chronic PJI, resulting in an eradication rate of just 44.4% [15]. However, compared to these options, antibiotic-impregnated, bioabsorbable calcium sulfate beads placed into infected joints provide much greater long-term antibiotic control, while still offering comparable ease of use. An in vitro antibiotic elution study individually studying vancomycin-, gentamicin-, tobramycin-, and rifampicin-loaded beads found that the eluted concentrations of each surpassed the reported minimum inhibitory concentration for common PJI pathogens during the entire 42-day study period [16]. In the context of these findings, the use of dissolvable antibiotic-loaded calcium sulfate beads has received strong interest as an adjunct treatment to improve PJI treatment outcomes, particularly DAIR procedures [17]. However, to our knowledge, there are no comparative existing studies that have evaluated the efficacy of these beads in DAIRs against a control group in the acute or acute hematogenous PJI setting.

The objective of this study was to address this literature gap through a matched retrospective cohort study. We sought to determine if there was a difference in infection-related failures at 2 years and 90 days postoperatively after DAIR for acute and acute hematogenous PJs between patients who received adjunct dissolvable antibiotic-loaded calcium sulfate beads and those who did not.

**Material and methods**

After obtaining institutional review board approval, we performed a retrospective review of all DAIR procedures for THA or TKA PJI performed at our institution in which antibiotic-loaded calcium sulfate beads were used as an adjunctive treatment (cases) over a 6-year period (2013-2018). These were compared to a matched cohort of patients who were treated with DAIR but without the use of antibiotic-loaded calcium sulfate beads (controls; Fig. 1).

Patients were identified using our institutional database according to the International Classification of Diseases-10 code for PJI (T84.50XA) and included in this study only if they met the 2018 Musculoskeletal Infection Society criteria for diagnosis of PJI [18]. All PJI infections in this study were either acute (occurring within 6 weeks of the index procedure) or acute hematogenous (defined as infections presenting with no more than 6 weeks of symptoms in a previously well-functioning prosthesis) as per the 2018 International Consensus Meeting on Periprosthetic Joint Infection [19,20].

Patients with chronic PJI were excluded.

Our institutional protocol for DAIR involves arthrotomy and open debridement of the joint, complete synovectomy, and copious pulsatile lavage with antibiotic saline. Exchange of all modular components (head/liner in THA; polyethylene liner in TKA) is performed as either general anesthesia or regional anesthesia. Patients were also treated with further adjuncts such as a 3-minute intra-articular dilute povidone-iodine, 10% povidone-iodine, and/or hydrogen peroxide wash before closure. Intraoperative lavage was classified as either general bactericidal, consisting of just antibiotic saline solution, or adjunctive, if povidone-iodine and/or peroxide solutions were also used. Postoperatively, each patient was treated with pathogen-specific antibiotic control, while still offering comparable ease of use.

**Figure 1.** Dissolvable antibiotic-loaded calcium sulfate beads implanted during a DAIR for PJI in a TKA. (a) Clinical intraoperative photograph with beads in the suprapatella pouch, lateral and medial gutters. (b) Postoperative radiograph demonstrating bead location in the suprapatella pouch, lateral, and medial gutters.
intravenous antibiotics via a peripherally inserted central catheter for a minimum period of 6 weeks under the supervision of a board-certified infectious disease specialist. Patients were hospitalized until wounds were dry, and they were able to be safely discharged home or to a rehabilitation facility. All patients were monitored in multidisciplinary outpatient clinics every 2 weeks.

For this study, patient demographics including age and body mass index (BMI), preoperative erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Charlson Comorbidity Index (CCI) were recorded. In addition, case details for the index DAIR procedure, including the joint operated on, intraoperative lavage volume, use of an intra-articular antiseptic solution, use and dosage of calcium sulfate beads, and intraoperative culture results, as well as any infection-related revisions at 90 days or 2 years postoperatively, were collected.

**Statistical analysis**

Patients were exactly matched on CCI. Our primary outcome was infection-related revision within 2 years of the index DAIR procedure. Our secondary outcome was early infection-related revision occurring within 90 days of the index DAIR. McNemar’s test was used to evaluate for differences between groups for our secondary outcome (infection-related revision within 2 years of the index DAIR). The Wilcoxon signed-rank test was used to evaluate for differences between groups for our primary outcome (infection-related revision within 90 days of the index DAIR based on intraoperative considerations). This was evenly distributed among the groups, with 8 of these patients found in both the cases and controls (P = .99).

Within the case group, the dose of antibiotics used in calcium sulfate beads was available for 18 patients (90%) and varied according to the size of the patient and/or surgeon preference: Fifty percent of the cases used a 10 cc pack (1.2 g of tobramycin + 1 g of vancomycin), 28% used 20 cc (2.4 g of tobramycin + 2 g of vancomycin), and the remaining 22% used 30 cc (3.6 g of tobramycin + 3 g of vancomycin).

**Outcomes**

In total, 14 patients (35%) required a revision surgery at 2-year follow-up because of recurrence of PJI. There was no statistically

---

**Table 1**

| Demographic          | Cases (n = 20) | Matched controls (n = 20) | P value |
|----------------------|---------------|--------------------------|---------|
|                      | Mean          | Std. dev.                | Mean    | Std. dev. |
| Sex                  |               |                          |         |
| Male (%)             | 60            | 55                       | 40      | 45        |
| Female (%)           | 40            | 45                       | 60      | 80        |
| Joint                |               |                          |         |
| Total hip replacement (%) | 40           | 20                       |         |
| Total knee replacement (%) | 60           | 80                       |         |
| Age (y)              | 72.1 ± 11.8   | 71.1 ± 8.2               | .97     |
| BMI (kg/m²)          | 34.0 ± 7.5    | 32.0 ± 7.3               | .42     |
| CRP (mg/L)           | 15.0 ± 9.9    | 14.2 ± 11.4              | .22     |

**Table 2**

| Culture result                  | Cases (n = 20) | Matched control (n = 20) |
|---------------------------------|---------------|-------------------------|
|                                 | Frequency     | Percent                 | Frequency | Percent |
| Methicillin-sensitive *Staphylococcus aureus* | 7            | 35                      | 3         | 15      |
| Methicillin-sensitive *Staphylococcus epidermidis* | 1            | 5                       | 1         | 5       |
| Methicillin-resistant *S. aureus* | 4            | 20                      | 3         | 15      |
| Methicillin-resistant *S. epidermidis* | 1            | 5                       | 5         | 25      |
| *Escherichia coli*              | 1             | 5                       | 0         | 0       |
| *Enterobacter cloacae*          | 1             | 5                       | 0         | 0       |
| *Enterococcus faecalis*         | 0             | 0                       | 1         | 5       |
| Group A *Streptococcus*         | 1             | 5                       | 0         | 0       |
| Group B *Streptococcus*         | 1             | 5                       | 1         | 5       |
| *Acinetobacter baumannii*       | 1             | 5                       | 0         | 0       |
| *Morganella morganii*           | 0             | 0                       | 1         | 5       |
| *Proteus mirabilis*             | 0             | 0                       | 1         | 5       |
| *Pseudomonas aeruginos*         | 0             | 0                       | 1         | 5       |
| Culture negative                | 2             | 10                      | 3         | 15      |

There was no difference in overall microbial spectra (P = .38) or antibiotic-resistant organisms (P = .54) between groups.
Discussion

In addition, we examined infection-related early failure (occurring within the first 90 days postoperatively). Two patients (5%) from the entire cohort underwent a revision procedure within 90 days of their index DAIR procedure. There was no statistically significant difference between cases (n = 1, 5%) and controls (n = 1, 5%) for this outcome (P = 1.00). These outcome breakdowns are summarized in Table 4.

Outcomes after DAIR for both groups.

There was no statistically significant difference between cases (n = 9, 45%) and controls (n = 5, 25%) for this outcome (P = .21).

In additional modeling, we examined infection-related early failure (occurring within the first 90 days postoperatively). Two patients (5%) from the entire cohort underwent a revision procedure within 90 days of their index DAIR procedure. There was no statistically significant difference between cases (n = 1, 5%) and controls (n = 1, 5%) for this outcome (P = 1.00). These outcome breakdowns are summarized in Table 4.

### Table 3

| Intraoperative irrigation                        | Cases (n = 20) | Matched control (n = 20) | P value |
|-----------------------------------------------|----------------|--------------------------|---------|
|                                              | Mean/Frequency | Percent                  | Mean/Frequency | Percent |         |
| Irrigation amount                             |                |                         |                |         |         |
| Antibiotic saline (general bactericidal)      | 9.9 L          | 40                       | 8.3 L          | 25      | .31     |
| Antibiotic saline + povidone-iodine and/or peroxide (adjunctive) | 12             | 60                       | 15             | 75      |         |

There was no difference in irrigation solution type (general bactericidal or adjunctive) between groups (P = .31).

### Table 4

| Postoperative outcome                        | Cases (n = 20) | Matched control (n = 20) | P value |
|----------------------------------------------|----------------|--------------------------|---------|
|                                              | Frequency      | Percent                  | Frequency | Percent |         |
| Failure for recurrent infection at 2 y       | 9              | 45                       | 5        | 25      | .21     |
| Failure for early infection within 90 d      | 1              | 5                        | 1        | 5       | 1.00    |

There was no statistically significant difference for infection-related failure at either 2 years or 90 days postoperatively.
There are several important limitations to consider in our study. First, this is a retrospective review with a matched cohort comparison; an ideal study design would have been a blinded RCT, but an RCT may not be feasible. Second, modular implant exchange was not performed for each DAIR case because of patient-specific intraoperative considerations. We recognize that this contravenes current consensus recommendations and has been shown to be a key negative prognosticator for DAIR success [32]. However, these instances were equally distributed between the case and control groups, mitigating the effect that modular implant retention may have had on differences in failure rates. Furthermore, this study reflects the pragmatic intraoperative decision-making made in real time. Finally, the sample size of this study was limited. However, this is attributable to strict inclusion criteria, as all patients met the most recent 2018 Musculoskeletal Infection Society PJL criteria and qualified as having acute or acute-hematogenous PJs during their index DAIR according to the definitions outlined in the 2018 International Consensus Meeting. In addition, virtually all potential confounding variables were accounted for, including an exact CCI-match for patient comorbidities and statistically equivalent distributions of patient demographics, preoperative inflammatory markers, microbiology and antibiotic-resistance profiles, and intraoperative lavage adjuncts. Thus, we believe we were able to reliably isolate the effect of antibiotic calcium sulfate beads on DAIR outcomes in this study design.

Conclusion

In this case-control study of acute or acute-hematogenous PJs treated with DAIR with and without adjunct dissolvable antibiotic beads, we found no clinically meaningful improvements in DAIR outcomes when beads were used. This finding, combined with the significant cost and the potential for hypercalcemia and increased polyethylene wear, necessitates further investigation into the efficacy, cost-effectiveness, and safety of antibiotic-loaded synthetic calcium sulfate bead use during DAIR procedures for the treatment of PJL. Based on current data, we believe there is little justification to use antibiotic-loaded calcium sulfate beads during DAIR in the treatment of PJL.

Conflicts of interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A. Carli is a paid consultant for Heraeus Medical. C. W. Jones gave a paid presentation at the Revision Knee Masters Symposium DePuy Synthes, Sydney, March 2019, and received institutional research funding from Zimmer Biomet. P. K. Sculco is in the speakers’ bureau of or gave paid presentations for DePuy Synthes, Intellijoint Surgical, and EOS imaging; is a paid consultant for DePuy Synthes, Intellijoint Surgical, Lima Corporate, and EOS imaging; and receives research support from Intellijoint Surgical. All other authors have no conflicts to disclose.

For full disclosure statements refer to https://doi.org/10.1016/j.arth.2022.01.023.

References

[1] Kurtz SM, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are we winning or losing the battle with periprosthetic joint infection: trends in periprosthetic joint infection and mortality risk for the Medicare population. J Arthroplasty 2018;33:3238.
[2] Toulson C, Walcott-Sapp S, Hurr J, et al. Treatment of infected total hip arthroplasty with a 2-stage reimplantation protocol. Update on “our institution’s” experience from 1989 to 2003. J Arthroplasty 2005;24:1051.
[3] Koyonos L, Zmistowski B, della Valle CJ, Parvizi J. Infection control rate of debridement and antibiotic treatment for periprosthetic joint infection. Clin Orthop Relat Res 2011;469(11):3043.
[4] Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the workgroup of the musculoskeletal infection society. Clin Orthop Relat Res 2011;469(11):2992.
[5] Xu Y, Wang L, Xu W. Risk factors affect success rate of debridement, antibiotics and implant retention (DAIR) in periprosthetic joint infection. Arthroplasty 2020;2:1.
[6] Barros LH, Barbosa TA, Esteves J, Abreu M, Soares D, Sousa R. Early Debridement-antibiotics and implant retention (DAIR) in patients with suspected acute infection after hip or knee arthroplasty - safe, effective and without negative functional impact. J Bone Jt Infect 2019;4:300.
[7] Sousa A, Carvalho A, Pereira C, et al. Economic impact of periprosthetic joint infection - an evaluation within the Portuguese National Health System. J Bone Jt Infect 2018;3:197.
[8] Jacobs AME, Valkering ULP, Bénard M, Meiss JF, Goosen JHM. Evaluation one year after DAIR treatment in 91 suspected early prosthetic joint infections in primary knee and hip arthroplasty. J Bone Jt Infect 2019;4:5:238.
[9] Zhang CF, He L, Yu FX, et al. Debridement, antibiotics, and implant retention for acute periprosthetic joint infection. Orthop Surg 2020;12:2:463.
[10] Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic joint infections treated by open debridement and retention of components. J Arthroplasty 2009;24:6 Suppl); 101.
[11] Khaliq H, Hersh BL, Kreger A, et al. Benefits and adverse events associated with extended antibiotic use in total knee arthroplasty periprosthetic joint infection. Clin Infect Dis 2020;70(4):559.
[12] Chung JY, Ha CW, Park YB, Song YJ, Yu KJ. Arthroscopic debridement for vancomycin-impregnated infected tibial prosthesis: any role for infection control and prosthetic salvage? Arthroscopy 2013;30(5):599.
[13] Urish KL, DeMuth PW, Craft DW, Haider H, Davis CM. Pulse lavage is inadequate at removal of biofilm from the surface of total knee arthroplasty materials. J Arthroplasty 2014;29(6):1128.
[14] Riego AM, Park BK, Herrero CP, Yu S, Schwarzkopf R, Iorio R. Vancomycin-povidone-iodine protocol improves survivorship of periprosthetic joint infection treated with irrigation and debridement. J Arthroplasty 2018;33:847.
[15] Kildow BJ, Patel SP, Otero JE, et al. Results of irrigation and debridement for PJL with the use of intraosseous antibiotics. Orthop Proc 2020;102-B(6 Supple A); 185.
[16] Aiken SS, Cooper JF, Florance H, Robinson MT, Michell S. Local release of antibiotics for surgical site infection management using high-purity calcium sulphate: an in vitro elution study. Surg Infect (Larchmt) 2015;16(1):54.
[17] Risitano S, Sabatini L, Atzori F, Massé A, Indelli PF. Static antibiotic spacers augmented by calcium sulphate impregnated beads in revision TKA: surgical technique and review of literature. J Orthop 2018;15(2):313.
[18] Parvizi J, Tan TL, Goswami K, et al. The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. J Arthroplasty 2018;33(5):1309.
[19] Schwarzw EM, Parvizi J, Gehrke T, et al. 2018 International consensus meeting on musculoskeletal infection: research priorities from the general assembly questions. J Orthop Res 2019;37(5):997.
[20] Saeed K, McLaren AC, Schwarz EM, et al. 2018 International consensus meeting on musculoskeletal infection: summary from the biofilm workshop and consensus on biofilm related musculoskeletal infections. J Orthop Res 2019;37(5):1007.
[21] McKeever MD, Li-Bland EA, Wild LM, Schematisch EH. A prospective, randomized, double-blind trial comparing an antibiotic-impregnated bioabsorbable bone substitute with standard antibiotic-impregnated cement beads in the treatment of chronic osteomyelitis and infected nonunion. J Orthop Trauma 2010;24(8):483.
[22] McPherson EJ, Dipane MV, Shervin R. Dissolvable antibiotic beads in treatment of periprosthetic joint infection and revision arthroplasty the use of synthetic pure calcium sulfate (Stimulan®) impregnated with vancomycin & tobramycin. Reconst Review 2013;3:32–43.
[23] Aboudia A, Ali M. The use of calcium sulphate beads in periprosthetic joint infection, a systematic review. J Bone Jt Infect 2020;5(1):41.
[24] Flierl MA, Cup BM, Okroj KT, Springer BD, Levine BR, della Valle CJ. Poor outcomes of irrigation and debridement in acute periprosthetic joint infection using antibiotic-impregnated calcium sulfate beads. J Arthroplasty 2017;32(8):2505.
[25] Gramlich Y, Johnson J, Kemmerer M, Walter G, Hoffmann R, Klug A. Salvage procedure for chronic periprosthetic knee infection: the application of DAIR results in better remission rates and infection-free survivorship when used with topical degradable calcium-based antibiotics. Knee Surg Sports Traumatol Arthrosc 2020;28(9):2823.
[26] Kallala R, Haddad FS. Hypercalcemia following the use of antibiotic-eluting absorbable calcium sulphate beads in revision arthroplasty for infection. Bone Joint J 2015;97-B(9):1:1237.
[27] Zhu MF, Kim K, Cavadino A, Coleman B, Munro JF, Young SW. Success rates of debridement, antibiotics, and implant retention in 230 infected total knee arthroplasties: implications for classification of periprosthetic joint infection. Arthroplasty 2021;36(1):305.
[28] Tornero E, Martinez-Pastor JC, Bori G, et al. Risk factors for failure in early prosthetic joint infection treated with debridement. Influence of etiology and antibiotic treatment. J Appl Biomater Funct Mater 2014;12(3):125.
Tornero E, Morata L, Martínez-Pastor J, et al. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clin Microbiol Infect 2015;21(8):786.e9.

Lebeaux D, Ghigo J-M, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev 2014;78(3):510.

Heuberger R, Wahl P, Krieg J, Czerner E. Low in vitro third-body wear on total hip prostheses induced by calcium sulphate used for local antibiotic therapy. Eur Cells Mater 2014;28:246.

Wouthuysen-Braken M, Scholtes M, Lomas I, et al. Timing of implant removal in late acute periprosthetic joint infection: a multicenter observational study. J Infect 2015;70(3):195.